You are here

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

TitleA randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.
Publication TypeJournal Article
Year of Publication2014
AuthorsWohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, Zolopa A, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J
Corporate AuthorsGS-US-236-0102 Study Team
JournalJ Acquir Immune Defic Syndr
Volume65
Issue3
Paginatione118-20
Date Published2014 Mar 01
ISSN1944-7884
KeywordsAdolescent, Adult, Anti-HIV Agents, Anti-Retroviral Agents, Double-Blind Method, Drug Combinations, Female, HIV Infections, HIV-1, Humans, Male, Tablets, Time Factors, Treatment Outcome, Young Adult
DOI10.1097/QAI.0000000000000057
Alternate JournalJ. Acquir. Immune Defic. Syndr.
PubMed ID24256630
Grant ListP30 AI050410 / AI / NIAID NIH HHS / United States